Evidence map›Paper›PMID 36589208›Full record

ArticleNeuroscience and behavioral physiology2022

Neurological Signs of Postcovid Syndrome.

P R Kamchatnov, R A Cheremin, L A Skipetrova, A V Chugunov

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience and behavioral physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

P R KamchatnovPirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
R A ChereminSpeech Pathology and Neurorehabilitation Center, Moscow Health Department, Moscow, Russia.
L A SkipetrovaSpeech Pathology and Neurorehabilitation Center, Moscow Health Department, Moscow, Russia.
A V ChugunovPirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
Center for Speech Pathology and Neurorehabilitation · RUMinistry of Health of the Russian Federation · RUPirogov Russian National Research Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The challenge of postcovid syndrome (PCS) is of great interest due to its wide distribution and variety of clinical signs. The main neurological signs of PCS are discussed. Data on the presumptive mechanisms forming PCS are presented. The potential for using the drug Mexidol to treat patients with PCS is addressed.

Indexed as

chronic cerebral ischemiacognitive impairmentsCOVID-19Mexidolpostcovid syndrometreatment

Identifiers

PMID36589208
PMCPMC9789305
OpenAlexW4312215179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.